Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Capricor Therapeutics, Inc.

CAPRNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 13, 2026Accepted Nov 13, 2026, 4:02 PM ESTFiling CIK 1569064Accession 0000919574-26-007761
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Capricor Therapeutics, Inc.
Company CIK
0001133869
Street
10865 Road to the Cure
Street (continued)
Suite 150
City
San Diego
State / country code
CA
Postal code
92121

Statement details

Amendment number
1
Security class
Common Stock, par value $0.001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Montanova Capital, LLC
Citizenship / organization
DE
Reporting person type
IA · OO
Group designation
b
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Averill Master Fund, Ltd.
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Aaron Cowen
Citizenship / organization
X1
Reporting person type
HC · IN
Group designation
b
Aggregate amount owned
0.00
Percent of class
0
Sole voting power
0.00
Shared voting power
0.00
Sole dispositive power
0.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Item 1

Issuer

Capricor Therapeutics, Inc.

Principal executive office address

10865 Road to the Cure, Suite 150, San Diego, California 92121

Item 2

Citizenship

Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States

Filing person

Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen

Principal business or residence address

Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America

Item 3

Not applicable indication

Y

Item 4

Percent of class

Montanova Capital, LLC - 0% Averill Master Fund, Ltd. - 0% Aaron Cowen - 00%

Amount beneficially owned

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Sole voting power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Shared voting power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Sole dispositive power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Shared dispositive power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, $0.01 par value.

Item 7

Not applicable indication

N

Subsidiaries

Please see Exhibit B attached hereto.

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

Signature comments

* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Signature 1

Reporting person
Montanova Capital, LLC
Signed
/s/ Andrew Nathanson
Title
Andrew Nathanson, General Counsel and Chief Compliance Officer
Date
11/13/2026

Signature 2

Reporting person
Averill Master Fund, Ltd.
Signed
/s/ Andrew Nathanson
Title
Andrew Nathanson, Authorized Signatory
Date
11/13/2026

Signature 3

Reporting person
Aaron Cowen
Signed
/s/ Aaron Cowen
Title
Aaron Cowen
Date
11/13/2026

Filed exhibits

Company context

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 10, 2026
  2. Results of Operations and Financial ConditionNov 10, 2026
  3. SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Sep 14, 2026
  4. Other EventsAug 24, 2026
  5. SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Aug 19, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.